SmartLipids in Drug Delivery: Redefining the Third Generation of Lipid Nanocarriers for Clinical and Industrial Translation

SmartLipids represent the third generation of lipid-based nanocarriers, emerging as a transformative innovation in modern drug delivery and formulation science. Evolving from solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), SmartLipids overcome key limitations such as low drug loading, polymorphic instability, and limited scalability. Characterized by a "chaotic" matrix of 5-10 structurally diverse lipids, SmartLipids enable high encapsulation efficiency, enhanced physical and chemical stability, tunable drug release, and improved penetration and bioavailability for both lipophilic and amphiphilic molecules. This comprehensive review elucidates their rational design principles, formulation strategies, and key physicochemical and biological characterization parameters, supported by recent preclinical findings demonstrating superior cytocompatibility, permeability, and controlled release performance. Furthermore, we discuss the industrial translation of SmartLipids under Quality by Design (QbD) frameworks, their regulatory prospects, and their expanding applications beyond cosmetics, spanning oral, mucosal, and gene delivery systems. Collectively, SmartLipids bridge the gap between bench-scale innovation and clinical translation, offering a versatile, stable, and scalable platform for next-generation nanomedicines.